61 results on '"MS Hematologie"'
Search Results
2. Predictors of outcomes in hematopoietic cell transplantation for Fanconi anemia
3. A non-randomized risk-adjusted comparison of lenalidomide + R-CHOP versus R-CHOP for MYC-rearranged DLBCL patients
4. The management of light chain (AL) amyloidosis in Europe: clinical characteristics, treatment patterns, and efficacy outcomes between 2004 and 2018
5. Allogeneic hematopoietic cell transplantation in patients with CALR-mutated myelofibrosis: a study of the Chronic Malignancies Working Party of EBMT
6. Fresh or frozen grafts for allogeneic stem cell transplantation: conceptual considerations and a survey on the practice during the COVID-19 pandemic from the EBMT Infectious Diseases Working Party (IDWP) and Cellular Therapy & Immunobiology Working Party (CTIWP)
7. Current use of fecal microbiota transfer in patients with hematologic diseases: a survey on behalf of the Cellular Therapy and Immunobiology Working Party of the EBMT
8. The European Society for Blood and Marrow Transplantation (EBMT) roadmap and perspectives to improve nutritional care in patients undergoing hematopoietic stem cell transplantation on behalf of the Cellular Therapy and Immunobiology Working Party (CTIWP) and the Nurses Group (NG) of the EBMT
9. Carfilzomib, lenalidomide and dexamethasone followed by a second ASCT is an effective strategy in first relapse multiple myeloma: a study on behalf of the Chronic malignancies working party of the EBMT
10. Disseminated nontuberculous mycobacterial infections after allogeneic hematopoietic stem cell transplantation: a risk-based strategy for early diagnosis
11. Long-term outcome of second allogeneic hematopoietic stem cell transplantation (HSCT2) for primary graft failure in patients with acute leukemia in remission: A study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
12. Graft engineering: how long can you wait, how low can you go, and pandemic readiness
13. Activity of ex vivo graft and DLI Engineering within the last decade increases, a survey from the EBMT Cellular Therapy & Immunobiology Working Party
14. Uncovering the mode of action of engineered T cells in patient cancer organoids
15. In response to: Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: results of the iStopMM study
16. R-CEOP as first-line treatment for anthracycline-ineligible patients with diffuse large B-cell lymphoma
17. Increased mortality risk in multiple-myeloma patients with subsequent malignancies: a population-based study in the Netherlands
18. Correction to: Predictive factors for vaccine failure to guide vaccination in allogeneic hematopoietic stem cell transplant recipients (Bone Marrow Transplantation, (2021), 56, 12, (2922-2928), 10.1038/s41409-021-01437-0)
19. Daratumumab after allogeneic hematopoietic cell transplantation for multiple myeloma is safe and synergies with pre-existing chronic graft versus host disease. A retrospective study from the CMWP EBMT
20. Results of a multicenter phase I/II trial of TCR alpha beta and CD19-depleted haploidentical hematopoietic stem cell transplantation for adult and pediatric patients
21. Defining the impact of SARS-COV-2 on delivery of CAR T-cell therapy in Europe: a retrospective survey from the CTIWP of the EBMT
22. Impact of donor-derived CD34 + infused cell dose on outcomes of patients undergoing allo-HCT following reduced intensity regimen for myelofibrosis: a study from the Chronic Malignancies Working Party of the EBMT
23. Decrease in early mortality for newly diagnosed multiple myeloma patients in the Netherlands: a population-based study
24. Predictive factors for vaccine failure to guide vaccination in allogeneic hematopoietic stem cell transplant recipients
25. Anti-thymocyte globulin with CsA and MMF as GVHD prophylaxis in nonmyeloablative HLA-mismatched allogeneic HCT
26. Comparing outcomes of a second allogeneic hematopoietic cell transplant using HLA-matched unrelated versus T-cell replete haploidentical donors in relapsed acute lymphoblastic leukemia: a study of the Acute Leukemia Working Party of EBMT
27. Second allogeneic transplants for multiple myeloma: a report from the EBMT Chronic Malignancies Working Party
28. Phosphatase PP2A enhances MCL-1 protein half-life in multiple myeloma cells
29. Therapeutic outcome of early-phase clinical trials in multiple myeloma: a meta-analysis
30. TEG001 Insert Integrity from Vector Producer Cells until Medicinal Product
31. The complex genetic landscape of familial MDS and AML reveals pathogenic germline variants
32. EBV-related lymphoma after long-term daratumumab treatment: a case report
33. Correction: Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS
34. Comparison of reduced-intensity conditioning regimens in patients with acute lymphoblastic leukemia >45 years undergoing allogeneic stem cell transplantation-a retrospective study by the Acute Leukemia Working Party of EBMT
35. Benchmarking of survival outcomes following haematopoietic stem cell transplantation: A review of existing processes and the introduction of an international system from the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) (vol 55, pg 681, 2019): Benchmarking of survival outcomes following haematopoietic stem cell transplantation: A review of existing processes and the introduction of an international system from the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) (Bone Marrow Transplantation, (2020), 55, 4, (681-694), 10.1038/s41409-019-0718-7)
36. Efficacy of MSC for steroid-refractory acute GVHD associates with MSC donor age and a defined molecular profile
37. Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS
38. Prophylactic, preemptive, and curative treatment for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a position statement from an international expert group
39. Fludarabine/busulfan versus fludarabine/total-body-irradiation (2 Gy) as conditioning prior to allogeneic stem cell transplantation in patients (≥60 years) with acute myelogenous leukemia: a study of the acute leukemia working party of the EBMT
40. Death after hematopoietic stem cell transplantation: changes over calendar year time, infections and associated factors
41. Benchmarking of survival outcomes following haematopoietic stem cell transplantation: A review of existing processes and the introduction of an international system from the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)
42. Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019
43. The EBMT activity survey report 2017: a focus on allogeneic HCT for nonmalignant indications and on the use of non-HCT cell therapies
44. Tyrosine kinase inhibitor levels matter in treating chronic GVHD
45. Immune monitoring in allogeneic hematopoietic stem cell transplant recipients: a survey from the EBMT-CTIWP
46. 89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer
47. Erratum: Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells
48. Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial
49. Haematopoietic stem cell transplantation for autoimmune diseases
50. Jon van Rood (1926-2017)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.